We have located links that may give you full text access.
Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, double-blind, parallel group, randomized placebo-controlled trial.
Complementary Therapies in Medicine 2023 Februrary 25
INTRODUCTION: Kalmegh (Andrographis paniculata) iscommonly used for treating uncomplicated Upper Respiratory TractInfection (URTI) in complementary and alternative system of medicine. Ap-Bio®(Kalmcold®) is a standardized extract derived from the leaves of A. paniculata. This study was proposed to evaluate its efficacy using validated scales and objective measures.
METHODS: Participants were randomized in a ratio of 1:1:1 to receive either Ap-Bio® 200mg/day, Ap-Bio® 400mg/day or placebo for 7 days. The primary outcome measure was Wisconsin Upper Respiratory Symptom Survey (WURSS-21) score. The secondary outcome measures were nasal mucous weight, nasal muco-ciliary clearance function and IL-8 in nasal wash, as well as safety and tolerability.
RESULTS: A total of n=331 participants were screened and N=300 participants were enrolled. The absolute WURSS-21 global score [mean (Standard Deviation - SD)] in the Ap-Bio® 400mg group [5.70 (5.31)] was less than the Ap-Bio® 200mg group [5.81 (4.83)] on Day-3. However, it was much higher in the placebo group [9.55 (14.27)]. AP-Bio® 400mg group (Mean Difference - MD [Standard Error - SE] = -3.85 [1.52]; 95% CI = -6.85, - 0.85; adjusted p = 0.034) and 200mg group (MD [SE] = -3.74 [1.51]; 95% CI = -6.73, - 0.76; adjusted p = 0.038) had significantly lower score than placebo. Similarly, on D3, the change in global score from baseline was significantly better in the AP-Bio® 400mg group (MD [SE] = -3.91; [1.82] 95% CI = -7.50, - 0.32; adjusted p = 0.038) and AP-Bio® 200mg group (MD [SE] = -3.84 [1.97]; 95% CI = -7.72, - 0.04; adjusted p = 0.044) in comparison to the placebo group. Nasal mucous weight, tissue paper counts used, and interleukin-8 showed a trend towards Ap-Bio®groups having a favourable outcome when compared with placebo but did not reach statistical significance due to a small sample size. None of the study participants complained of any adverse physical symptoms. However, incident eosinophilia was noted in n=20 participants on day 3. (n=6 in Ap-Bio® 200mg group, n= 7 in Ap-Bio® 400mg group and n=13 in placebo group; p = 0.181).
CONCLUSIONS: Participants in both the Ap-Bio®dose groups showed positive tendency towards resolution of URTI symptoms when compared with placebo on Day-3 but not on Day-5 and Day-7.
METHODS: Participants were randomized in a ratio of 1:1:1 to receive either Ap-Bio® 200mg/day, Ap-Bio® 400mg/day or placebo for 7 days. The primary outcome measure was Wisconsin Upper Respiratory Symptom Survey (WURSS-21) score. The secondary outcome measures were nasal mucous weight, nasal muco-ciliary clearance function and IL-8 in nasal wash, as well as safety and tolerability.
RESULTS: A total of n=331 participants were screened and N=300 participants were enrolled. The absolute WURSS-21 global score [mean (Standard Deviation - SD)] in the Ap-Bio® 400mg group [5.70 (5.31)] was less than the Ap-Bio® 200mg group [5.81 (4.83)] on Day-3. However, it was much higher in the placebo group [9.55 (14.27)]. AP-Bio® 400mg group (Mean Difference - MD [Standard Error - SE] = -3.85 [1.52]; 95% CI = -6.85, - 0.85; adjusted p = 0.034) and 200mg group (MD [SE] = -3.74 [1.51]; 95% CI = -6.73, - 0.76; adjusted p = 0.038) had significantly lower score than placebo. Similarly, on D3, the change in global score from baseline was significantly better in the AP-Bio® 400mg group (MD [SE] = -3.91; [1.82] 95% CI = -7.50, - 0.32; adjusted p = 0.038) and AP-Bio® 200mg group (MD [SE] = -3.84 [1.97]; 95% CI = -7.72, - 0.04; adjusted p = 0.044) in comparison to the placebo group. Nasal mucous weight, tissue paper counts used, and interleukin-8 showed a trend towards Ap-Bio®groups having a favourable outcome when compared with placebo but did not reach statistical significance due to a small sample size. None of the study participants complained of any adverse physical symptoms. However, incident eosinophilia was noted in n=20 participants on day 3. (n=6 in Ap-Bio® 200mg group, n= 7 in Ap-Bio® 400mg group and n=13 in placebo group; p = 0.181).
CONCLUSIONS: Participants in both the Ap-Bio®dose groups showed positive tendency towards resolution of URTI symptoms when compared with placebo on Day-3 but not on Day-5 and Day-7.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app